Randomized Controlled Trial

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

N. Engl. J. Med. 2016 Aug 25; 375 (8): 754-66.
Multicenter Study

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.

N. Engl. J. Med. 2015 Sep 24; 373 (13): 1207-19.
Randomized Controlled Trial

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

Lancet. 2016 Apr 9; 387 (10027): 155115601551-1560.